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Abstract
Background: Aberrant expression of cyclin D1 is a common feature in multiple myeloma (MM) and always associated 
with mantle cell lymphoma (MCL). CCND1 gene is alternatively spliced to produce two cyclin D1 mRNA isoforms which 
are translated in two proteins: cyclin D1a and cyclin D1b. Both isoforms are present in MM cell lines and primary cells 
but their relative role in the tumorigenic process is still elusive.
Results: To test the tumorigenic potential of cyclin D1b in vivo, we generated cell clones derived from the non-CCND1 
expressing MM LP-1 cell line, synthesizing either cyclin D1b or cyclin K, a structural homolog and viral oncogenic form 
of cyclin D1a. Immunocompromised mice injected s.c. with LP-1K or LP-1D1b cells develop tumors at the site of 
injection. Genome-wide analysis of LP-1-derived cells indicated that several cellular processes were altered by cyclin 
D1b and/or cyclin K expression such as cell metabolism, signal transduction, regulation of transcription and translation. 
Importantly, cyclin K and cyclin D1b have no major action on cell cycle or apoptosis regulatory genes. Moreover, they 
impact differently cell functions. Cyclin K-expressing cells have lost their migration properties and display enhanced 
clonogenic capacities. Cyclin D1b promotes tumorigenesis through the stimulation of angiogenesis.
Conclusions: Our study indicates that cyclin D1b participates into MM pathogenesis via previously unrevealed actions.
Background
Cyclin D1 is a key actor for the development and progres-
sion of various cancers including hematological malig-
nancies. The human CCND1 gene generates two mRNA
species by alternative splicing [1]. The two corresponding
proteins cyclin D1a and D1b differ only in the last 55
amino acids of the carboxy-terminus. Both isoforms pos-
sess the N-terminal domain, necessary for retinoblas-
toma protein (pRb) binding, the cyclin box, required for
cyclin-dependent kinase (CDK) binding and activation
and the central region, implicated in transcriptional regu-
lation. The PEST sequence which controls protein turn-
over and the threonine 286 (Thr286), the site of phospho-
rylation by glycogen synthase kinase-3β which promotes
the nuclear export of cyclin D1 and its degradation
through the proteasome pathway [2,3], are present only
in cyclin D1a. The oncogenic potential of cyclin D1
seems restricted to the isoform b as shown in vitro [4-6].
In transgenic mouse models, inhibition of cyclin D1 pro-
teolysis is the causative factor for mammary carcinomas
and B-cell lymphomas [7,8]. The mechanisms of cyclin
D1b-mediated tumorigenesis are not fully understood
and could depend on the cellular context and in particu-
lar on the concomitant expression of cyclin D1a.
Cyclin K is encoded by Kaposi sarcoma-associated her-
pes virus (KSHV), a human tumor virus associated with
the development of Kaposi sarcoma and lymphoid malig-
nancies in immunocompromised individuals, reviewed in
[9]. Cyclin K and cyclin D1 share sequence colinearity
and identity. The tumorigenic properties of cyclin K have
been demonstrated in transgenic animals in which the
lymphocyte compartment has been targeted [10]. In a
similar transgenic model, cyclin D1a alone fails to induce
leukemogenesis [11,12].
Mantle cell lymphoma (MCL) and multiple myeloma
(MM) are two hematological malignancies for which
cyclin D1 e xpr ession has been recognized as an onc o-
genic event [13,14]. Although cyclin D1a and D1b
mRNAs are present in all MCL and MM samples tested,
cyclin D1a protein is expressed predominantly [15,16].
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However, a role of cyclin D1b in the leukemogenic pro-
cess cannot be ruled out. In order to study the oncogenic
potential of cyclins D1b and K in the context of mature B
cells, we generated several cell clones derived from LP-1
MM cell line, expressing either cyclin D1b, Myc or cyclin
K oncogenes. LP-1 cell line was chosen because this MM
c e l l  l i n e  d o e s  n o t  e x p r e s s  a n y  c y c l i n  D 1  i s o f o r m .  W e
report here that cyclin D1b- and cyclin K-expressing LP-1
cells are tumorigenic in vivo in xenograft models.
Genome-wide analysis allowed us to describe several
mechanisms for cyclin D1b- and K-mediated oncogene-
sis.
Methods
Generation of LP-1-derived clones
LP-1 MM cell line which does not express cyclin D1 was
chosen for the generation of stable transfected clones.
GRANTA-519 MCL cell line has the t(11;14)(q13;q32)
and expresses high level of cyclin D1a. LP-1 and
GRANTA-519 cells were maintained in RPMI 1640 con-
taining 10% fetal calf serum (FCS), L-glutamine and anti-
biotics (Lonza Verviers SPRL, Verviers, Belgium).
p c D N A 3 - f l a g g e d  c y c l i n  K  [ 1 7 ]  ( a  g e n e r o u s  g i f t  o f  O .
Coqueret), pcDNA3-c-Myc (a generous gift of D. Cappel-
len) and pcDNA3-cyclin D1b [18] encode for the full-
length proteins, respectively. LP-1 cells were transfected
by electroporation, selected with 500 μg/ml G418, cloned
by limiting dilution in 96-well plates. Single clones were
individually tested for exogenous protein expression.
After three months in culture without loss of transgene
expression, G418 was first reduced and finally removed.
Cell cycle analysis by flow cytometry
Exponentially growing LP-1-derived cells were plated at a
density of 5 × 105 cells/ml, harvested 24 h later, fixed in
ice-cold EtOH 80% in PBS. Cells were treated with 100
μg/ml RNase A and 20 μg/ml propidium iodide (PI) for 30
min at 37°C. Cells were analyzed with an Epics XL flow
cytometer and data with the Expo™ 32 software (Beck-
man Coulter, Villepinte, France).
Matrigel invasion assay
LP-1-derived cells were suspended in FCS-free RPMI
1640 medium and 2 × 104 cells were placed in the upper
chamber of transwell inserts coated with Matrigel (BD
BioCoat Matrigel Invasion Chamber, BD Biosciences, Le
Pont de Claix, France). In the lower compartment, we
added RPMI 1640 medium plus 1% FCS. Plates were
incubated for 4 h at 37°C to allow migration of cells. After
incubation, inserts were carefully removed, washed, fixed
and colored to allow cell counting. Results are expressed
as the number of cells that invaded the Matrigel. Statisti-
cal analysis between two groups was done with the Stu-
dent's t test.
Clonogenicity assay
The ability of individual cell to grow in semi-solid sup-
port was assayed using MethoCult® (StemCell Technolo-
gies, Grenoble, France) according to the manufacturer'
instructions. Cells were prepared at a density of 3 × 103
cells/ml in Iscove's MDM plus 2% FCS; then added to the
same volume (3 ml) of methyl cellulose containing phyto-
hemagglutin-leucocyte conditioned medium (PHA-
LCM) as source of growth factor. Cells were dispensed in
triplicate in Petri dishes, incubated in humidified atmo-
sphere at 37°C for 10 days. Colonies containing more
than 50 cells were counted using inverted microscope
and gridded scoring dish.
Immunoblotting
Methods for protein extraction, SDS-PAGE and immu-
noblotting were described previously [18].
In vivo engraftment experiments
Female, six week-old nude mice (NMRI, Janvier, Le Gen-
est Saint-Isle, France), were inoculated s.c. with 2.5 × 106
(1st set) or 4 × 106 (2nd set) cells of the various clones in
Matrigel (BD Biosciences, v/v). Mice were regularly mon-
itored for the development of palpable tumors. Tumor
volumes based on caliper measurements were calculated
by the ellipsoidal formula [1/2 (length2 × width)]. The
first set of animals (five mice per clone) was sacrificed at
eight weeks (see Figure 1b). The second series of animals
(ten animals per clone) was sacrificed depending on the
tumor sizes (see Figure 2a). Tumors were then either
fixed in Finefix (Microm Microtech., Francheville,
France) or frozen for further analyses. In a third series of
experiment, the LP-1D1b clone (5 × 106 cells) was inocu-
lated in Matrigel into the lower flank of nude mice. The
day after, 10 μM of either scrambled siRNA (5'-aat tct ccg
aac gtg cac gt-3') or siRNA targeting VEGF (5'-aag gag acc
ctg atg aga tc-3') were mixed with AteloGene™ (Koken,
Cosmo Bio Co., Tokyo, Japan) according to manufac-
turer's instructions. The mixture (150 μl) was s.c. injected
wrapping up the cells at the injection site. Chemical
tyrosine kinase (TK) inhibitors targeting VEGFR2/3 (SAR
131675.13, (SAR)) and all FGFR (SSR 128129E.13, (SSR)),
a gift of F. Bono, were dissolved in 5% glucose in physio-
logical serum. SAR and SSR were i.v. injected biweekly at
40 mg/kg each, starting at day 1 following inoculation of
cells. Each group contained 5 mice. At day 11, volume of
tumors was measured as before and the growth of tumors
monitored thereafter. The tumor evolution was calcu-
lated as the ratio between the volume of tumors at each
time point and the volume of the tumors of non treated
mice at day 11. Statistical analysis for tumor evolution in
each group was done with the Student's t test. During the
experiments, mice had free access to food and water and
all the experiments were performed at the Common Ser-Marsaud et al. Molecular Cancer 2010, 9:103
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vice of Animal Experimentation (UFR de Pharmacie,
Châtenay-Malabry), in accordance to the declaration of
Helsinki on animal welfare and with the approval of the
ethics committee of the University of Paris 11/CNRS
(responsible person V. Dommergue-Dupont).
Immunohistochemistry of tumor sections
Finefix-fixed paraffin embedded 4 μm-sections were
deparaffinized in toluene twice for 5 min and rehydrated
by using graded EtOH concentrations. After antigen
retrieval in citrate buffer pH 6.2 (5 min, 85°C), immuno-
histochemical labeling with anti-CD138 or anti-CD34
antibodies (Abs) was performed with the Vector
Vectastain Elite kit (Vector Laboratories, Burlingame,
CA, USA) and 3',3' Diaminobenzidine (DAB) as chromo-
gen. Sections were counterstained with hemalun.
Microarray hybridization, gene expression data and 
statistical analyses
For each cell line (LP-1cl1, LP-1K and LP-1D1b), total
RNA was extracted from four independent cultures with
Trizol reagent (Invitrogen, Cergy Pontoise, France)
according to the manufacturer' instructions and used for
expression analysis on a 25K human oligonucleotide
microarray covering most of the known human tran-
scripts. The 50 mers 5'-amino modified oligonucleotides
from the RNG/MRC oligonucleotide collection [19]
(information available at http://www.microarray.fr:8080/
merge/index) were diluted to a final concentration of 50
Figure 1 Cyclin D1b and cyclin K are oncogenic in nude mice. a) Generation of LP-1-derived clones. Total proteins were extracted from individual 
clones, resolved by SDS-PAGE (12%) and immunoblotted with anti-cyclin D1 Ab which detects both cyclin D1a and b isoforms (DCS-6, BD Biosciences, 
Le Pont de Claix, France), anti-c-Myc Ab (sc-764, Santa Cruz Biotech., Santa Cruz, CA, USA), anti-Flag M2 Ab (Sigma-Aldrich, Saint Quentin Fallavier, 
France) which detects cyclin K construct. Anti-β-tubulin Ab (sc-9104, Santa Cruz biotech.) was used to control gel loading and transfer, GRANTA-519 
cell line was used as control for cyclin D1a expression. The four clones then referred as LP-1cl1, LP-1D1b, LP-1 Myc and LP-1K marked with an asterisk 
(*) were injected in vivo. b) Each cell clone was injected with Matrigel s.c. in 5 nude mice which were sacrificed 8 weeks later. The number of mice with 
a tumor at the site of injection is presented in the histogram; two representative mice bearing tumor are shown as well as hematoxylin-eosin-safran 
(HES) staining of tumor sections.
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mM in 50% dimethyl sulfoxide, 100 mM potassium phos-
phate (pH 8.0) and printed onto hydrogel-coated slides
(Nexterion H slides, Schott, Jena, Germany) using a
microGrid II arrayer (Genomic Solutions, Cambridge,
UK). Total RNAs (200 ng) were amplified by linear PCR
and labelled with Cy3 using Bioprime Array CGH
Genomic Labelling System Kit (Invitrogen). Total RNA
from one culture of LP-1cl1 cells was similarly amplified,
labelled with Cy5 and used as a reference probe for
hybridization. Each Cy3-labelled probe was co-hybrid-
ized with the Cy5 reference probe on microarrays in a
G2545A oven (Agilent, Massy, France) at 60°C for 18 h.
Microarrays were washed (10 min in 6× SSC, 0.005% Tri-
ton-X100; 5 min in 0.1× SSC, 0.0025% Triton-X100) and
scanned with a G2565B scanner (Agilent). Raw data were
extracted from scanned microarray images (.tif) using
Feature Extraction Software v9.5 (Agilent) and normal-
ized using the Quantile method adapted to bicolour
microarrays. All the protocols used can be obtained by
contacting the microarray and sequencing platform of the
IGBMC (web site: http://www-microarrays.u-strasbg.fr/).
In order to select genes that are differentially expressed
among the three biological groups (LP-1cl1, LP-1K and
LP-1D1b), we performed an analysis of variance using
Cy5/Cy3 log2 ratios. To limit the error due to multiple
tests, we used permutation of samples for controlling the
false discovery rate [20]. Genes with a p-value less than
0.01 were considered to be significant. Moreover, we fil-
tered out genes with a fold change (FC). The FC between
LP-1K and LP-1cl1 was calculated as the median value of
the 4 replicates ratios in the LP-1K samples over the
median value of the 4 replicates ratios in the LP-1cl1 sam-
Figure 2 The engrafment potential of LP-1K and LP-1D1b does not rely on exacerbated proliferation properties. a) In a second set of engraft-
ment assay, mice were monitored for tumor appearance, and the volume of the tumor evaluated. In the histograms are indicated the number of mice 
bearing tumors four or eight weeks post-injection and the mean volume of tumors at that time. b) Fixed tumor sections were studied by conventional 
IHC for CD138 (brown staining) expression (40× magnification). Anti-CD138 Ab was purchased from Dako (Trappes, France). Sequential sections were 
incubated with the secondary Ab alone as negative control. c) LP-1 derived clones were plated at a density of 5 × 105 cells/ml, cells were harvested 
24 h later, fixed in EtOH, stained with PI and analyzed with an Epics XL flow cytometer and Expo™32 software (Beckman Coulter). For each series, 10,000 
to 20,000 events were gated. The percentage of cells within each cell cycle phase (G0/G1, S, G2/M) is indicated on the graph, the apoptotic cells (ap) 
are in the sub-G1 fraction.
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ples. Three FC were calculated: LP-1K vs. LP-1cl1, LP-
1D1b vs. LP-1cl1 and LP-1K vs. LP-1D1b and a threshold
equal to 2 was used for selecting three lists of significant
genes. To design Venn diagram, we used the VENNY
software http://bioinfogp.cnb.csic.es/tools/venny/ and
individual gene expression profiles were generated with
the TigrMev 4_03 software http://www.tm4.org/
mev.html. To determine functional relationships between
genes, we used DAVID Bioinformatics Resources http://
david.niaid.nih.gov.
Real-time quantitative RT-PCR
T o val ida t e  t he  m icr oa rra y da ta, we  used RNAs  pr evi-
ously used for microarray hybridization. Primers for
36B4, CSN2, FGFR3, FHIT, HSP90B1, TUBB2B, TFRC,
CD48,  LTB,  FN1,  BCL2,  CDK6,  GAPDH  and  UCHL1
genes were designed with the LightCycler® Probe Design
software (Roche Diagnostics, Meylan, France). Their
sequences are reported in the Additional File 1, Table S1.
Q-PCR was carried out in a LightCycler® system (Roche
Diagnostics) using the LightCycler® FastStart DNA master
SYBR Green I kit (Roche Diagnostics) according to the
manufacturer's instructions. Cycles were as follows: a 10
min initial cycle at 95°C, followed by 45 cycles of 10 sec of
denaturation at 95°C, 5 sec of annealing at 58°C, and 10
sec of extension at 72°C. The specificity of the fluores-
cence was verified by the melting curve analysis after
each reaction. The relative abundance of each target was
normalized to 36B4 expression and the quantification of
each mRNA compared to 36B4 was done using the com-
parative threshold method (Ct).
Tumor engraftment onto chick chorio-allantoic membrane
Fertilized chicken eggs (EARL Morizeau, Dangers,
France) were handled as described previously [21]. On
embryonic day 10, a plastic ring was placed on chick cho-
rio-allantoic membrane (CAM) and 107 LP-1K or LP-
1D1b cells in 30 μl Matrigel (BD Biosciences) were depos-
ited after gentle laceration of the surface. Digital pictures
were taken under a stereomicroscope (Nikon SMZ1500)
at day 2, 4, 6 of tumor development. Twenty eggs were
used for each condition.
Results
Cyclin D1b, cyclin K and c-Myc expressing LP-1-derived 
clones display tumorigenic properties
Stable LP-1 clones were generated by transfection of
cyclin D1b-, cyclin K- or c-Myc-expressing pcDNA3 plas-
mids or empty pcDNA3 as control. As shown Figure 1a,
in the two clones LP-1 D1b (1 and 2), the short isoform b
of cyclin D1 was expressed (clone 1) or overexpressed
(clone 2) at a level comparable to the one in GRANTA-
519 MCL cell line which possesses the t(11;14)(q13;q32)
and synthesizes high level of cyclin D1a. Endogenous c-
Myc was present in the control LP-1 pcDNA3 clone 1,
and exogenous c-Myc was overexpressed (×5) in the two
LP-1 c-Myc-expressing clones. In the LP-1 CK clone,
cyclin K was detected with the anti-Flag M2 Ab. A repre-
sentative clone from each series (star in Figure 1a), there-
after referred as LP-1cl1 (control), LP-1K, LP-1 Myc or
LP-1D1b was injected s.c. into a first set of five nude mice.
Eight weeks after injection, tumors were present at the
site of inoculation in 4/5 mice for LP-1K, 5/5 mice for LP-
1 Myc and 3/5 mice for LP-1D1b (Figure 1b) but not in
mice inoculated with the control clone LP-1cl1. Only one
mouse developed a palpable lump (pseudo-tumor, which
regresses spontaneously). Macroscopically, tumors were
distinguishable from one clone to the other, cyclin D1b-
induced tumors being bigger and highly vascularized.
After hematoxilin-eosin-safran (HES) staining of fixed
tumor sections, histology revealed the presence of typical
malignant plasma cells (Figure 1b). In a second series of
in vivo experiments, 10 animals per cell line were inocu-
lated. Four weeks after injection, tumors were detected at
the site of inoculation in 10/10 mice for LP-1K and 6/10
mice for LP-1D1b (Figure 2a). Five mice from each series
were sacrificed and the others monitored for four more
weeks. At that time, four more mice in the LP-1D1b
series bore tumors. The most striking differences
between the two series were the size of the tumors (Fig-
ure 2a) and again the rich vascularization of LP-1D1b
tumors (data not shown). Immunohistological examina-
tion of tumor sections indicated that engrafted tumors
contained  bona fide myeloma cells expressing CD138
(Figure 2b). Our data show unambiguously that such as c-
Myc, cyclin D1b and cyclin K are capable to confer a
malignant phenotype to LP-1 MM cells and are onco-
genic in vivo.
Cyclin D1b and cyclin K are not mitogenic in LP-1 cells
We used flow cytometry sorting of PI-stained exponen-
tially growing cells to assess the cell proliferation capaci-
ties of LP-1-derived clones. As presented in Figure 2c, the
overexpression of cyclin D1b, cyclin K or c-Myc did not
enhance the percentage of cells within the S phase of the
cell cycle. By contrast, both LP-1D1b and LP-1K exhib-
ited spontaneous apoptosis. In LP-1K cells, we observed a
concomitant decrease of DNA synthesizing cells. We
concluded from these data that the oncogenic properties
acquired by LP-1 cells do not rely on an exacerbated pro-
liferation potential.
Cyclin D1b and cyclin K expression alter LP-1 cells 
transcriptome
We used transcriptome analysis to evaluate cyclin D1b-
and cyclin K-induced changes in LP-1 cells. Microarray
data and annotations have been deposed in the NIH gene
expression Omnibus under accession number GSE15497.Marsaud et al. Molecular Cancer 2010, 9:103
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A Venn diagram was used to visualize the overlap
between three data sets: LP-1K vs. LP-1cl1, LP-1D1b vs.
LP-1cl1, LP-1K vs. LP-1D1b (FC>2, Figure 3a). This dia-
gram shows that the expression of cyclin K had major
effects on LP-1 transcriptome (593+444+90+1628
sequences were modified); less sequences were altered by
both cyclin D1b and cyclin K (444+90) or cyclin D1b
alone (156+153). We then filtered sequences to select
genes coding for proteins having known biological func-
tions and FC>3 to limit the number of genes to study. The
number of genes up- or down-regulated in LP-1K or/and
LP-1D1b cells is indicated in Figure 3b. Individual gene
expression profiles were generated with the TigrMev
4_03 software (Additional File 2 Figure S1, Additional File
3 Figure S2 and Additional File 4 Figure S3). We then
hierarchically clustered genes on the basis of their biolog-
ical processes (Figure 3c). Numerous genes implicated in
metabolism, signal transduction, transport, transcrip-
tional and translational regulations were modified by
cyclin K and/or cyclin D1b. Unexpectedly, genes regulat-
ing cell cycle, apoptosis, cell proliferation were less
numerous. Genes involved in cell structure and cell
motion were specifically modified by cyclin K, whereas
genes regulating hematopoiesis were modified by cyclin
D1b. Our data indicate that the transformation process
elicited by cyclin D1b and cyclin K involved a broad range
of cellular processes.
Cyclin D1b and cyclin K alter cell cycle and survival genes 
expression
Real-time RT-PCR was performed for validation of
microarray results (Table 1). We found a good correlation
between microarray and RT-PCR data for the altered
expression of 7 genes in LP-1D1b and 6 genes in LP-1K.
Figure 3 Transcriptome datasets. a) The Venn diagram drawn with VENNY software shows the overlaps between the sequences that are the most 
differentially expressed across the three transcriptome datasets (LP-1K vs. LP-1cl1, LP-1D1b vs. LP-1cl1 and LP-1K vs. LP-1D1b, FC>2). b) We filtered 
genes coding for proteins involved in biological processes and having a FC>3. We have eliminated from the raw data: doublets, UG clusters corre-
sponding to "data not found", sequences with no gene ontology (GO)-associated terms, non specific terms such as "open reading frame", "hypothet-
ical" and "IMAGE"-containing terms. c) Functions were attributed to genes with DAVID tools. The percentage of altered genes involved in the various 
cellular functions is indicated by numbers.
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Western blots, flow cytometry (data not shown) and
immunocytochemical assays further confirmed tran-
scriptional data (Figure 4a, b). Among the genes encoding
cell cycle-associated proteins altered in LP-1 derivatives
(Table 2 and data not shown), we confirmed the down-
regulation of cyclin D2 in LP-1D1b cells (FC: -2.05), the
downregulation of CDK2 in LP-1K cells (FC: -2.10), the
complete disappearance of p18INK4C  in LP-1K cells, a
clear decrease of p53 level in LP-1K cells (Figure 4a).
Although the level of transcription of the TP53 gene itself
was not modified in LP-1K vs. LP-1cl1 cells, the tran-
scription of two genes coding for two proteins involved in
p53 stabilization were downregulated. These two pro-
teins are the tumor protein p53 inducible protein 3
(TP53I3, FC: -3.57) and binding protein 2 (TP53BP2, FC:
-2.12).  CDKN2B mRNA was decreased both in LP-1K
and LP-1D1b cells. However, at the protein level, no
major differences were seen between LP-1cl1 and LP-
1D1b whereas p15INK4B disappeared totally in LP-1K cells
(Figure 4a). Differences of post-transcriptional mecha-
nisms in each cell line could explain this variation
between microarray and western blot data.
Then, we analyzed the status of signalization pathways
in LP-1 cells. Indeed, microarray data indicated that
either signalization from transmembrane receptors (epi-
thelial growth factor receptor (EGFR), tumor necrosis
factor receptor (TNFR), hepatocyte growth factor recep-
tor (HGFR), interleukin-21 receptor (IL-21R) etc.) or sig-
nalization molecules belonging to the phosphoinositol-3
kinase (PI3K)/AKT, Janus kinase (JAK)/signal transducer
and activator of transcription 3 (STAT3), mitogen-acti-
vated protein kinase (MAPK), nuclear factor (NF)-κB
could be altered in LP-1 derived cells (Table 3). This was
verified by immunoblotting (Figure 4b). The STAT3 path-
way is constitutively activated in LP-1 cells. In LP-1K
cells, this pathway is overactivated as shown by the
hyperphosphorylation of STAT3 both in the cytoplasmic
and nuclear compartments. The MAPK pathway is acti-
vated in LP-1K cells whereas the p70S6K pathway is acti-
vated in LP-1D1b cells. The AKT protein is
downregulated in LP-1K cells. These data underline that,
although structurally related, cyclin D1b and cyclin K are
able to activate/inhibit different signaling pathways con-
trolling survival and/or proliferation.
The large number of genes and pathways altered by
cyclin D1b and/or cyclin K expression precludes a thor-
ough analysis in this manuscript. We focused on two dis-
crete functions of cyclins D-type identified by the
Table 1: Real-time quantitative RT-PCR for validation of microarray data
Gene Microarray data ΔCt (Ct LP-1D1b-Ct LP-1cl1) Fold change FC (microarray)
36B4 nm* -0.78/-0.52/-0.42** 1 -
CSN2 +7.33 -2.16/-2.70 +7.67/+6.34 +7.33
FGFR3 +5.07 -2.78/-1.62 +11.79/+4.25 +5.09
FHIT +4.67 -1.41/-1.10 +3.68/+3.68 +4.67
HSP90B1 +2.25 -1.21 +3.20 +2.26
TUBB2B -2.32 1.01 -1.45 -2.32
TFRC -6.48 3.77/3.14 -9.51/-6.36 -6.48
CD48 -12.27 4.05/4.18 -9.64/-13.08 -12.27
Gene Microarray data ΔCt (Ct LP-1K- Ct LP-1cl1) Fold change FC (microarray)
36B4 nm* -0.25/-0.40/-0.20/-0.36 1 -
LTB +40.66 -5.7 +43.71 +40.67
FN1 +13.54 -3.55 +8.87 +13.54
BCL2 +3.17 -2.36 +3.89 +3.17
CDK6 -4.14 1.83/1.95 -4.08/-4.43 -4.14
GAPDH -5.15 1.09 -2.44 -6.15
UCHL1 -63.82 11.11/11.25 -2538/-2797 -63.82
* nm, not modified. **When several numbers are indicated, they refer to the results obtained with different runs of PCR. For each sample, the 
average Ct value for the internal standard 36B4 was subtracted from the average Ct value for each gene to yield ΔCt. The relative amount of 
each mRNA compared to the calibrator (36B4) in each run was calculated by the formula N = 2-ΔΔCt to give the fold change. For each gene, the 
Fc calculated from microarray data (in bold) is reported in the right column.Marsaud et al. Molecular Cancer 2010, 9:103
http://www.molecular-cancer.com/content/9/1/103
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microarray analysis and well-known as support for tum-
origenic process: cell migration and angiogenesis.
Cyclin K inhibits migration of LP-1-derived clones and 
enhances its clonogenic capacities
When observed with an inverted optical microscope, LP-
1-derived clones exhibited different morphologies (Fig-
ure 5a). Compared to LP-1cl1 cells, LP-1D1b formed
clusters of cells whereas LP-1K cells grew individually. At
the transcriptional level, LP-1K but not LP-1D1b cells
displayed major alterations of genes coding for attach-
ment proteins such as integrins, lamin B, ADAMs,
ICAMs, CD47 (Table 4). Explaining new morphological
properties of the cells, we found that the gene ITGB7
coding for integrin β7, recognized as a major promoter of
MM cell proliferation trough interactions with stroma
cells [22] was downregulated in LP-1D1b cells and upreg-
ulated in LP-1K cells. LP-1K cells showed enhanced clo-
nogenic capacities when plated in semi-solid medium
compared to LP-1cl1 and LP-1D1b which showed similar
capacities (Figure 5b). Cyclin D1 regulates cell prolifera-
tion and cell migration of mammary epithelial cells
through the stabilization of p27Kip1 and its phosphoryla-
tion of a Ser10 residue [23]. We analyzed the level and the
phosphorylated status of p27Kip1  in LP-1-derived cell
clones (Figure 5c). Both the levels of p27Kip1 protein and
its phosphorylated form were lower in LP-1D1b cells
than in LP-1cl1 and p27Kip1 was no longer expressed in
LP-1K cells both in the nuclear and cytoplasmic compart-
ments. These results argue that cyclins D1b and K fail to
stabilize p27Kip1. We next studied the migration proper-
ties of LP-1-derived clones by the Matrigel invasion assay.
Compared to LP-1cl1 cells, LP-1D1b had a similar capac-
ity to migrate whereas LP-1K cells had completely lost
this migratory property (Figure 5d).
Cyclin D1b allows neo-angiogenesis of engrafted tumors
LP-1 cells such as myeloma cell lines synthesize angio-
genic factors such as vascular endothelial growth factor
(VEGF) (data not shown). Cyclin D1b and/or cyclin K
Figure 4 Cyclin K and cyclin D1b impact the biology of LP-1 cells. Proteins from exponentially growing cells were resolved by SDS-PAGE and im-
munoblotted with the following Abs: anti-cyclin D2 (sc-181), anti-CDK2 (sc-6248), anti-p15 (sc-612), anti-p18 (sc-865), anti-β-tubulin (sc-9104) from 
Santa Cruz Biotech.; anti-p53 (Ab-1, Calbiochem, Merck Chemicals Ltd., Nottingham, UK); anti-p44/42 MAPK (#9102), anti-phospho-p44/42 MAPK 
(Thr202/Tyr204) (#9101), anti-p70S6K (#9202), anti-phospho-p70S6K (Thr389) (#9205), anti-AKT (#9272), anti-phospho-AKT (Thr308) (#4055), anti-Stat3 
(#9132), anti-phospho-Stat3 (Ser727) (#9134, Cell Signaling Technology, Danvers, MA, USA). Blots were reprobed with an anti-β-tubulin Ab as control 
of charge and transfer.
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expression in LP-1 cells impacted on proangiogenic and
antiangiogenic gene expression (Table 5). Compared with
LP-1K-, LP-1D1b-derived tumors were highly vascular-
ized (Figure 1b). This was confirmed by IHC after label-
ing the CD34 antigen present on vessel endothelial cells.
As observed in Figure 6a, CD34 staining is detected
mainly in LP-1D1b-derived tumors. The CAM assay was
performed to evaluate the direct effect of cyclins D1b and
K on tumor engraftment and tumor-mediated angiogene-
sis. Both cyclin D1b- and cyclin K-expressing LP-1 cells
were able to generate tumors in the CAM model within
few days. As shown in Figure 6b, LP-1D1b cells gave rise
to evolutive tumors characterized by higher volume and
significantly greater vascularization than LP-1K cells.
Tortuous capillaries are visible at the surface of LP-1D1b
tumors while LP-1K tumors, characterized by lack of size
progress, were not perfused. Thus, cyclin D1b promotes
neoangiogenesis and consequently, tumor growth in vivo.
To confirm the involvement of neoangiogenesis in tum-
origenesis of LP-1D1b cells in xenografts, we injected
either once VEGF siRNA (or the control scrambled
siRNA) at the vicinity of the injection site or biweekly ,
chemical FGFR or VEGFR inhibitors, SSR and SAR
respectively. As shown Figure 6c, as expected, scrambled
siRNA had no effects on tumor evolution. Administration
of VEGF siRNA markedly diminished the volume of LP-
1D1b-derived tumors for a 15 day-period. After 15 days,
no more effects of VEGF siRNA were observed likely due
to siRNA degradation and the tumor grew with a rate
similar to the one of control. This is in agreement with
the reported stability of siRNA in the delivery gel [24].
Importantly, SSR and SAR inhibitors completely abol-
ished the growth of tumors indicating a role of FGFR and
VEGFR in the tumor evolution. The capacity of VEGF
siRNA as well as TK inhibitors to inhibit tumor growth
strongly supports microarray and CAM data and the con-
clusion that cyclin D1b favors tumorigenesis through
activation of a neoangiogenic process.
Discussion
Cyclin D1 is overexpressed in a broad range of solid
malignancies, expressed in lymphoid tumors such as MM
Table 2: Genes coding for cell cycle regulatory molecules displaying altered expression in LP-1 derivatives (|FC|>3)
Gene Protein LP-1D1b vs. cl1 LP-1K vs. cl1
SESN2 Sestrin 2 +3.36* nm**
DDIT3 DNA-damage-inducible transcript 3 +3.35 nm
CCNB1IP1 Cyclin B1 interacting protein 1 nm +10.36
RASSF5 Ras association (RalGDS/AP-6) domain 
family member 5
nm +4.79
CDNK1A Cyclin-dependent kinase inhibitor 1A nm +4.30
CABLES1 CDK5 and ABL enzyme substract 1 nm +3.30
MAD2L1 MAD2 mitotic arrest deficient-like 1 nm -3.13
CCNB2 Cyclin B2 nm -3.14
GAS2 Growth-arrest specific 2 nm -3.22
MK167 Antigen identified by monoclonal antibody 
Ki67
nm -3.37
PINX1 PIN2-interacting protein 1 nm -3.57
CCNF Cyclin F nm -3.65
CKS2 CDC28 protein kinase regulatory subunit 2 nm -3.68
CHMP1A Chromatin modifying protein 1A nm -3.87
CDK6 Cyclin-dependent kinase 6 nm -4.14
CCNB1 Cyclin B1 nm -5.23
CDKN3 Cyclin-dependent kinase inhibitor 3 nm -6.53
CDKN2C Cyclin-dependent kinase inhibitor 2C (p18) nm -8.18
CDKN2B Cyclin-dependent kinase inhibitor 2B (p15) -3.75 -2.83
* Numbers are the fold change of the sample compared to LP-1cl1; ** nm, not modified.Marsaud et al. Molecular Cancer 2010, 9:103
http://www.molecular-cancer.com/content/9/1/103
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and MCL and not in their normal counterparts. However,
in vivo studies failed to reveal a strong oncogenic poten-
tial of the conventional cyclin D1, referred to cyclin D1a
[11,12]. By contrast, the cyclin D1 isoform b and the
mutant cyclin D1 T286A are capable to transform cells in
vitro [4-6] and to induce tumors in vivo [7,8]. These two
forms of cyclin D1 share a strict nuclear localization sug-
gesting that nuclear functions of cyclin D1 are necessary
and/or sufficient for tumor formation. Mutations of the
CCND1 gene disrupting the phosphorylation at Thr286
and thereby leading to nuclear accumulation of cyclin D1
have been described in endometrial and esophageal car-
cinomas further reinforcing this notion [25,26]. However,
the molecular mechanisms of cyclin D1b-driven tumori-
genesis are not fully elucidated. In cultured cells, cyclin
D1b is not capable to activate its catalytic partner CDK4
and in turn, does not regulate positively the cell cycle
[5,18], retains a strong transcriptional co-repressor activ-
ity, displays reduced binding to p27Kip1 and does not con-
trol cell migration [23]. Here we show that, in the context
of MM cells, cyclin D1b confers a full malignant pheno-
type and allows cells engraftment in immune-compro-
mised mice. The genome-wide analysis of LP-1D1b cells
extends our understanding of the biological properties of
cyclin D1b. Moreover, we have identified genes regulated
by cyclin K, a viral oncogenic homolog of cyclin D1a and
confirm the fundamental differences between the two
cyclin D1 isoforms.
Cyclin D1b and cyclin K alter LP-1 cells metabolism
The tumorigenic properties of cyclins D1b and K are not
conferred by an exacerbated proliferation. LP-1D1b and
LP-1K cells display the same proliferation properties and
cyclin D1b or cyclin K expressions have no major impact
on cell cycle regulation. Conversely, genes involved in
metabolism, signal transduction, transport, transcrip-
tional and translational regulations are profoundly
altered by cyclin D1b and/or cyclin K. In vivo, cyclin D1
inhibits oxidative glycolysis, lipogenesis, and mitochon-
drial gene activity in the mammary epithelium [27,28]. In
both LP-1K and LP-1D1b cells, the gene transcription of
LDHA  (lactate dehydrogenase, FC: -4.37 and -10.78,
respectively),  GAPDH  (glyceraldehyde-3-phosphate
dehydrogenase, FC: -4.94 and -3.17, respectively) and
ALDOA (aldolase A, FC: -2.69 and -3.73, respectively) is
decreased. These enzymes catalyze important energy-
yielding steps in carbohydrate metabolism. The expres-
sion of genes coding for key enzymes involved in oxida-
tive glycolysis such as pyruvate kinase (PKM2, FC: -3.57),
phosphoglycerate kinase 1 (PGK1, FC: -2.10), enolase 1
Table 3: Genes coding for signalization molecules displaying altered expression in LP-1 derivatives (|FC|>3)
Gene Protein LP-1D1b vs. cl1 LP-1K vs. cl1
FGFR3 Fibroblast growth factor 
receptor 3
+5.08* nm**
AKT3 v-akt oncogene homolog 3 nm -5.16
MET HGFR, Met proto-oncogene nm -4.33
ITPKA Inositol 1,4,5-triphosphate 3-
kinase A
nm -3.94
CD81 CD81 molecule nm +3.03
PIK3CG Phosphoinositide 3-kinase 
gamma
nm +3.20
DOK6 Docking protein 6 nm +3.21
MAPK13 MAP kinase 13 nm +3.25
ECOP EGFR-overexpressed protein nm +3.39
PRKD2 Protein kinase D2 nm +3.94
DUSP6 Dual specificity phosphatase 6 nm +8.37
SKAP1 Src kinase associated 
phosphoprotein
nm +9.28
SYK Spleen tyrosine kinase nm +9.87
MAPK12 MAP kinase 12 nm +10.10
BLK B lymphoid tyrosine kinase +2.39 +12.25
*, ** see legend of Table 2.Marsaud et al. Molecular Cancer 2010, 9:103
http://www.molecular-cancer.com/content/9/1/103
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(ENO1, FC: -2.32) in LP-1D1b cells; enolase 2 (ENO2, FC:
-2.82) in LP-1K cells are down-regulated. This suggests a
reduction of glycolysis in tumor cells and, therefore, such
as in mammary tumor cells, a paradoxical role of cyclin
D1 [27]. Indeed, most of tumor cells show an enhanced
glycolytic flux [29]. However, only fast growing tumor
cells display markedly modified energy metabolism and
multiple myeloma cells are considered as accumulating
cells rather than proliferating cells.
Cyclin D1b and cyclin K modulate gene transcription and 
translation within LP-1 cells
The roles of cyclin D1 in regulating signal transduction,
transcription and translation and their relevance in the
cellular transformation process are documented [30].
Among the candidate effectors of cyclin D1 in cancer
cells is the transcription factor C/EBPβ [31]. It has been
shown, in breast cancer cells, that C/EBPβ is a constitu-
tive repressor of cyclin D1 target genes and that cyclin D1
acts by antagonizing this repressor function. The disrup-
tion of signaling through C/EBPβ contributes to breast
cell transformation. Interestingly, in LP-1D1b cells, we
noticed the up-regulation of CEBPG (FC: +3.08), coding
for a close related transcription factor C/EBPγ whose
function in myeloma cells remains to be established. But
it is tempting to speculate some functional redundancy
between the two factors. Among the transcription factors
Figure 5 Cyclin D1b- and cyclin K-expressing LP-1 cells display opposite clonogenic and migration properties. a) Exponentially growing cells 
were observed with an inverted phase contrast microscope and photographed. b) Clonogenic assay of LP-1-derived clones. Cells were prepared at a 
density of 3 × 103 cells/ml in MethoCult® containing PHA-LCM as source of growth factor (StemCell Technologies). Cells were dispensed in triplicate 
in Petri dishes, incubated in humidified atmosphere at 37°C for 10 days. Colonies containing more than 50 cells were counted using inverted micro-
scope and gridded scoring dish. Each experiment was done in triplicate and repeated thrice. Results are expressed as mean ± SD. * p < 0.05 with the 
Student's t test. c) Western blot analysis of LP-1-derived clones. Either cytoplasmic or nuclear extracts were prepared, separated by 12% SDS-PAGE. 
Blots were then sequentially incubated with anti-p27Kip1 (sc-528), anti-phospho-p27Kip1 (sc-9104 from Santa Cruz Biotech.) Abs and anti-β-tubulin Ab 
to control gel loading and transfer. In the cytosolic and nuclear extracts from LP-1K cells, the anti-phospho-p27Kip1 Ab reveals a band which is not at 
the expected size and likely represents a non specific binding (black dot). d) Migration assay of LP-1-derived clones. SVF (1%) was placed in the lower 
chamber of a Matrigel-coated transwell, LP-1 cells were plated (2 × 104 cells) in the upper chamber, incubated 4 h at 37°C. After incubation, invading 
cells were fixed, stained and counted. Each experiment was done in triplicate and repeated thrice. Results are expressed as mean ± SD. * p < 0.05 with 
the Student's t test.
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Table 4: Genes coding for molecules controlling adhesion and movement displaying altered expression in LP-1 derivatives 
(|FC|>3).
Gene Protein LP-1D1b vs. cl1 LP-1K vs. cl1
CX3CR1 Chemokine (C-X-C motif) receptor 1 nm* +63.24**
CD99 CD99 molecule nm +52.47
FXYD5 FXY domain containing ion transport regulator 5 nm +43.74
CD9 CD9 molecule nm +35.80
SPON1 Spondin 1 nm +21.37
CD4 CD4 molecule nm +18.57
CXCL12 Chemokine (C-X-C motif) ligand 12 nm +17.26
ARGDIB RhoGDP dissociation inhibitor (GDI) beta nm +13.55
FN1 Fibronectin 1 nm +13.54
SUT3 SUT homolog 3 nm +13.44
ICAM3 Intracellular adhesion molecule 3 nm +13.34
LAMB3 Laminin beta 3 nm +12.74
PCDH1 Protocadherin 1 nm +12.05
CNTNAP2 Contactin associated protein-like 2 nm +11.79
MCAM Melanoma cell adhesion molecule nm +10.70
CCL2 Chemokine (C-C motif) ligand 2 nm +10.09
SYK Spleen tyrosine kinase nm +9.87
ANXA9 Annexin A9 nm +9.33
LAMA3 Laminin alpha 3 nm +8.46
LPXN Leupaxin nm +7.86
CD93 CD93 molecule nm +7.60
ERBB2IP Erbb2 interacting protein nm +6.12
NRCAM Neuronal cell adhesion molecule nm +6.09
ITGB2 Integrin beta 2 nm +6.08
PCDH1 Protocadherin 1 nm +5.77
CD97 CD97 molecule nm +5.38
ADAM23 ADAM metallopeptidase domain 23 nm +4.90
CTGF Connective tissue growth factor nm +4.60
CD36 CD36 molecule nm +4.53
NLGN1 Neuroligin nm +4.50
CD44 CD 44 molecule nm +4.21
CNTNAP2 Contactin associated protein-like 2 nm +4.03
CD33 CD33 molecule nm +4.02
HNT Neurtrimin nm +3.97
SELPLG Selectin P ligand nm +3.92
PKD2 Polycystic kidney disease nm +3.80
SIGLEC7 Sialic acid binding Ig-like lectin 7 nm +3.56
L1CAM L1 cell adhesion molecule nm +3.21
COL18A1 Collagen type XVIII alpha 1 nm +3.20
ADAM15 ADAM metallopeptidase domain 15 nm +3.18
CDSN Corneodesmosin nm +3.17
SIGLEC9 Sialic acid binding Ig-like lectin 9 nm +3.11Marsaud et al. Molecular Cancer 2010, 9:103
http://www.molecular-cancer.com/content/9/1/103
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altered by cyclin K and/or cyclin D1b expressions,
besides MYC, MAF, ETS family members, well-known as
major oncogenic actors in plasma cells [13], several oth-
ers have been implicated in myeloma pathology such as
ATF3/4, IRF4/8, NOTCH2, RUNX1/2, XBP1 through the
modulation of genes controlling growth, survival and
migration. All of them are altered in LP-1K and/or LP-
1 D 1 b  c e l ls  (T a b l e  6 ) .  I n  g ood  c o rr e la t i o n ,  s u rvi va l  a n d
proliferation properties of LP-1K and LP-1D1b cells are
modified compared with LP-1cl1 cells.
Eukaryotic initiation factors (eIFs) control translation
at the limiting step of initiation and several of them have
been recognized as major actors in transformation pro-
cesses [32]. In LP-1D1b cells, several genes coding for
eIFs are upregulated (EIF4EBP1, FC: +3.35; EIF3EIP, FC:
+2.79;  EIF4A2, FC: +2.50; EIF3F, FC: +2.05; EIF1, FC:
+2.02). By contrast, in LP-1K, EIF3A and EIF5 are down-
regulated (FC: -2.28 and -2.92, respectively). A more
active translation likely explains the faster growth of LP-
1D1b-derived tumors compared to LP-1K tumors.
Cyclin D1b and cyclin K have opposite action on LP-1 cells 
migration
Clinical observations indicate that cyclin D1 overexpres-
sion in human cancers correlate with metastasis. In cyclin
D1-/- mouse embryonic fibroblasts, cyclins D1a and b
have unique properties with regard to cell migration [33].
Cyclin D1a stabilizes p27Kip1 and inhibits RhoA-induced
ROCK kinase activity promoting cell migration while
cyclin D1b fails to stabilize p27Kip1 and has no effect on
cell migration. Our results confirm that cyclin D1b does
not affect LP-1 cells migration. Although cyclin K resem-
bles cyclin D1a in agreement with its known biological
functions: binding to CDK4/6, phosphorylation of pRb;
one prominent feature of its structure is the impairment
of p27Kip1 binding [34]. Accordingly, cyclin K expression
in LP-1 is associated with the absence of p27Kip1, the lack
of migration capacity and an enhanced clonogenic poten-
tial in vitro. Experiments assessing the metastatic poten-
tial of LP-1-derived cells in vivo are ongoing.
Cyclin D1b stimulates neoangiogenesis
Cyclin K/D1b-expressing cells, grafted onto the CAM of
chicken embryo, generate within a few days tumors
whose vascularization is significantly different. Tumors
obtained in nude mice after s.c. injection of LP-1-derived
cells show the same different vascularization. Indeed, LP-
1 MM cells overexpressing cyclin D1b markedly promote
tumor angiogenesis. Cyclin D1 regulates vascular
endothelial growth factor (VEGF) production and
thereby, growth of vascular endothelial cells and tumor
[35]. The inhibition of tumor growth after local injection
of VEGF siRNA confirmed a major role of VEGF in
tumor expesnion. This result was further reinforced by
the use of VEGFR inhibitors which could target either the
MM tumoral cells or their immediate environment.
Cyclins D1b and K induce transcriptional activation/inhi-
bition of proangiogenic/antiangiogenic factors. One
striking difference between the two cell lines is the over-
expression of FGFR3 in LP-1D1b cells. Activation of the
fibroblast growth factor 3 (FGFR3) expressed by
myeloma cells and its ligand FGF present in the mouse
could sustain in vivo angiogenesis such as in the bone
marrow milieu [36]. The expression of 402 angiogenesis-
associated genes has been studied in a large series of
patients with a MM or a MGUS (monoclonal gammopa-
thy of undetermined significance), considered as the pre-
malignant state of MM, MM cell lines and their normal
counterparts [37]. This study concluded that aberrant
NEO1 Neogenin homolog 1 nm -3.22
TROAP Trophilin-associated protein nm -3.60
ITGA6 Integrin alpha 6 nm -3.86
ITGAE Integrin alpha E nm -3.96
DST Distonin nm -4.00
COL24A1 Collagen type XXIV alpha 1 nm -4.07
JAM3 Junctional adhesion molecule 3 nm -4.26
PKP2 Plakophilin 2 nm -5.11
SPN Sialophorin (CD43) nm -5.55
JAM2 Junctional adhesion molecule 2 nm -12.09
ITGB7 Integrin beta7 -4.26 +4.65
*, ** see legend of Table 2.
Table 4: Genes coding for molecules controlling adhesion and movement displaying altered expression in LP-1 derivatives 
(|FC|>3). (Continued)Marsaud et al. Molecular Cancer 2010, 9:103
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Table 5: Genes coding for proangiogenic or antiangiogenic molecules displaying altered expression in LP-1 derivatives 
(|FC|>3).
Gene Protein LP-1D1b vs. cl1 LP-1K vs. cl1
FGFR3 Fibroblast growth factor receptor 3 +5.08* nm**
TNFRSF10B Tumor necrosis factor receptor superfamily 
member 10 B
+3.52 nm
GATA4 GATA binding protein 4 +2.15 nm
WARS Tryptophanyl-tRNA synthase +4.01 nm
IGFBP3 Insulin-like growth factor binding protein 3 nm +26.42
EPAS1 Endothelial PAS domain protein 1 nm +17.39
CXCL12 CXC chemokine ligand 12 nm +17.26
SLIT3 SLIT homolog 3 nm +13.44
CCL2 Chemokine ligand 2 nm +10.09
CXCL16 CXC chemokine ligand 16 nm +6.67
F11R F11 receptor nm +5.56
RUNX1 Runt-related transcription factor 1 nm +5.13
EGFL7 EGF-like domain multiple 7 nm +4.68
CTGF Connective tissue growth factor nm +4.60
TNFSF13 Tumor necrosis factor superfamily member 13 nm +4.57
SERPINB6 Serpin peptidase inhibitor clade B member 6 nm +4.53
PDGFB Platelet-derived growth factor beta nm +3.99
CXCL3 CXC chemokine ligand 3 nm +3.76
SERPINE2 Serpin peptidase inhibitor clade E member 2 nm +3.40
SERPINB1 Serpin peptidase inhibitor clade B member 1 nm +3.36
IL8 Interleukin 8 nm +3.30
MMP13 Matrix metallopeptidase 13 nm +3.12
IFNGR1 Interferon gamma receptor 1 nm +3.06
HAND2 Heart and neural crest derivatives nm -3.04
NRP2 Neuropilin nm -3.25
PTPRF Protein tyrosine phosphatase receptor type F nm -4.20
RUNX1T1 Runt-related transcription factor 1 translocated to 1 nm -4.79
ADM Adrenomedullin nm -6.66
ID1 Inhibitor of DNA binding 1 nm -8.32
LAMA3 Laminin alpha 3 nm +8.45
IFI16 Interferon gamma-inducible protein 16 nm +4.96
JAG2 Jagged 2 nm +4.77
ZFP36 Zinc finger protein 36 nm +3.60
ZFP36L2 Zinc finger protein 36 C3H type-like 2 nm +3.60
BMPR1A Bone morphogenetic protein receptor type 1A nm -3.65
PTPRM Protein tyrosine phosphatase receprot type M +2.11 +10.38
JDB2 Jun dimerization protein 2 +3.70 +3.74
IGF2BP1 Insulin-like growth factor 2 binding protein 1 -2.52 -5.70
COL9A1 Collagen type IX alpha 1 -3.41 -4.87
COL24A1 Collagen type XXIV alpha 1 -2.42 -4.07
DAPK1 Death-associated protein kinase 1 +2.48 -3.06
*, ** see legend of Table 2. Proangiogenic and antiangiogenic (in bold) genes are indicated.Marsaud et al. Molecular Cancer 2010, 9:103
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Page 15 of 19
expression of proangiogenic and downregulation of anti-
angiogenic genes occur in all MM patients. Interestingly
for our purpose, we noted that three genes were silent in
MGUS and expressed in MM, namely IL6,  FGF9  and
FGFR3. It is tempting to speculate that the expression of
FGFR3 triggers premalignant cells to enter a malignant
state as observed in our model.
Cyclin D1b and cyclin K activate major actors of MM 
tumorigenesis
Besides CCND1, several genes have been recognized as
major actors of MM tumorigenesis: CCND2,  MAF,
FGFR3, ITGB7 and CXCR3 [13]. All of them are altered in
either LP-1D1b or LP-1K cells. This observation validates
the use of LP-1-derived cells as a paradigm of tumorigen-
esis in MM. Moreover, based on previous microarray
analyses, genes implicated specifically in the tumorigenic
process of MM have been characterized [38-42]. Several
of them are also detected in our microarray analysis.
They code for proteins involved in metabolism, signal
transduction, transcription factors and cell cycle regula-
tors (Figure 7). Among them only a few number of genes
are recognized as tumorigenic in several MM models:
BCL2, BNIP3, FGFR3, MCL1, RAN and XBP1. BCL2 pro-
tein is the archetype of apoptosis regulatory molecules; it
is an integral outer mitochondrial membrane protein that
blocks the apoptotic death. BCL2 is often overexpressed
in transformed cells of the B lymphoid lineage, in malig-
nant compared to normal plasma cells [39]. By contrast
BNIP3 (BCL2/adenovirus E1B 19 kDa interacting protein
3) protein has pro-apoptotic function and BNIP3 gene is
repressed in MM cells through the methylation of its pro-
Figure 6 Cyclin D1b promotes tumor growth by stimulating angiogenesis. a) Fixed tumor sections were studied with conventional IHC for CD34 
(brown staining) expression. Anti-CD34 Ab (MEC14.7) was purchased from Hycult Biotech. (Uden, The Netherlands). Images (40× magnification) are 
representative of 3 experiments performed on 3 different tumors. b) Fertile eggs were incubated at 37.8°C and 80% humidity. On day 10, LP-1K and 
LP-1D1b cells (2 × 107 cells per egg) were inoculated on the CAM. At days 2, 4 and 6 after cells implantation, digital images of primary tumors were 
acquired at ×7.5 magnification. c) Five mice per condition were inoculated s.c. with LP-1D1b cells. For siRNA experiments, mice were injected the day 
after with a mixture of AteloGene™ and scrambled (green square) or VEGF (blue circle) siRNA. For chemical inhibitors experiments, mice were injected 
biweekly starting at day 1 following cell injection with SSR (purple circle) or SAR (red diamond). Non treated mice were used as controls (black triangle). 
The volume of tumors was measured at day 11 and during the period indicated and the tumor growth evaluated. The groups of mice injected with 
VEGF siRNA and untreated were compared at days 11 and 15; *, p < 0.05.
LP-1D1b LP-1K
a
Anti-CD34
LP-1K LP-1D1b
b
Day 2
Day 4
Day 6
c

Days after injection 
T
u
m
o
r
 
g
r
o
w
t
hMarsaud et al. Molecular Cancer 2010, 9:103
http://www.molecular-cancer.com/content/9/1/103
Page 16 of 19
moter [42]. MCL1 encodes two proteins belonging to the
BCL2 family with either pro- or antiapoptotic functions;
its overexpression has been detected in blood sample
from a myeloma patient but not in his twin [41]. The role
of the transcription factor XPB1 and the nuclear protein
RAN, a member of RAS family, in the myeloma patho-
genesis remains to be defined. The t(4;14)(p16.3;q32)
occurs in 15-20% of myeloma patients and leads to the
overexpression of FGFR3 gene and, in turn, the constitu-
tive activation of several signaling pathways in 80% of
t(4;14)+ MM patients. Five genes (ATF3,  BCKDHA,
FGFR3, RRM2 and SDC1) are altered by cyclin D1b alone
and six (BNIP3, CBS, CST3, HCLS1, RAN, SQSTM1) by
both cyclins D1b and K. Those findings question the rele-
vance of cyclin D1b expression in MM pathogenesis.
Is cyclin D1b involved in MM pathogenesis?
We have previously shown that both isoforms of cyclin
D1a and b mRNAs are present in MM cells and their rela-
tive levels similar. However, cyclin D1a isoform is pre-
dominant both in MM cell lines and primary cells [16]. It
has been thought that CCND1 alternative splicing was
regulated by a G/A polymorphism at the exon 4/intron 4
boundary [1]. It is now demonstrated that factors associ-
ated with chromatin remodelling and translation elonga-
tion largely contribute to cyclin D1b accumulation
[43,44]. This indicates that the regulation of cyclin D1b
Table 6: Genes coding for transcription factors displaying altered expression in LP-1 derivatives.
Gene Protein LP-1D1b vs. cl1 LP-1K vs. cl1
DDIT3 DNA-damage-inducible transcript 3 +3.34* nm**
ATF3 Activating transcription factor 3 +2.27 nm
XBP1 X-box binding protein 1 +2.24 nm
IRF8 Interferon regulatory factor 8 +2.21 nm
RUNX1 Runt-related transcription factor 1 nm +5.13
TCF4 Transcription factor 4 nm +4.40
MITF Microphtalmia-associated 
transcription factor
nm +3.50
NOTCH2 Notch homolog 2 nm +3.36
STAT5A Signal transduction and transcription 
factor 5A
nm +2.49
ETV6 Ets variant 6 nm +2.32
MAF v-maf musculoaponeurotic 
fibrosarcomaa oncogene homolog
nm +2.25
MYC v-myc myelocytomatosis viral 
oncogene homolog
nm +2.08
ETS2 v-ets erythroblastosis virus E26 
oncogene homolog
nm +2.06
IRF4 Interferon regulated factor 4 nm -2.25
RBPJ Recombination signal binding 
protein for Ig kappa region
nm -2.38
REL v-rel reticuloendotheliosis viral 
onvogene homolog
nm -3.63
RUNX2 Runt-related transcription factor 
related 2
nm -4.80
MYBL2 v-myb myeloblastosis viral oncogene 
homolog-like 2
nm -5.18
ATF4 Activating transcription factor 4 +2.75 +2.64
*, ** see legend of table 2. Since minor alterations in the level of transcription factors could have dramatic effects on gene expression, we 
sorted genes with a |FC|>2. Only genes coding for transcription factors recognized in the literature as relevant for myeloma pathogenesis are 
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level is complex and only the direct analysis of the cyclin
D1b protein could define its impact on disease. In a
recent large multiethnic case-control study, Knudsen and
his group showed that cyclin D1b is clearly elevated in a
significant fraction of primary breast tumors but with a
heterogeneous level within specimens and underex-
pressed in asynchronously proliferating cell lines [45,46].
They also show unambiguously that cyclin D1b levels are
associated with adverse prognostic outcome. Such an
analysis of cyclin D1b protein level in MGUS, the primary
step of MM and primary MM cells should be conducted
in order to definitely conclude on its role in MM patho-
genesis.
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